Gapping up
In reaction to strong earnings/guidance: CIEN +12.7%, AXAS +10.1%, VRNT +8.9%, VRA +6.5%, XNY +4.2%, MIXT +4.1%, JOY +3.7%, FIVE +2.9%, BV +2.9%, ( to divest PowerReviews for $30 mln , RLD +2.6%, NAV +1.2%, .
M&A news: S +3.2% (Bloomberg story that Sprint (S) and T-Mobile (TMUS) are near an agreement on price at $40/share, capital structure, and termination fee in potential deal), TMUS +0.9%.
Select Biotechrelated names showing strength: PRAN +9.4%, CPRX +6.9%, ISIS +4.4%, CYTR +1.6%.
Select CIEN peers trading higher: INFN +4.5%, JDSU +2.4%, JNPR +1.3%.
Other news: NEWL +43.5% (announces granting of temporary restraining order against Ironridge Global IV), HALO +15.6% (Halozyme Therapeutics to resume PEGPH20 clinical program in pancreatic cancer; FDA removes clinical hold on Phase 2 trial (study 202), GBLX +14.2% (provides shareholder update; 'will not be selling our GrowBLOX cultivation chambers to the retail consumer'),AXAS +10.1% (raised FY14 production guidance to 5500-5700 Boepd from 5200-5300 Boepd), SSLT +6.3% (still checking), NQ +3.9% (cont strength), TWTR +2.4% (previously considered buying music related companies such as Pandora (P)/Spotify/Soundcloud, according to FT story out yesterday afternoon; also initiated with Outperform at PacCrest), MDCO +2.4% (ORBACTIVTM Phase 3 trial results published in New England Journal of Medicine), SPR +2.2% (announced public secondary offering of ~8.17 mln shares of Class A common stock by selling stockholder; co to repurchase 4 mln shares), CETV +2.2% (announces the appointment of David Sturgeon as CFO), STO +2% (still checking), ORAN +2% (won a global wide area network and embedded security services contract with Oetiker Group), OLED +1.8% (Board of directors approved $50 mln common stock repurchase program), MNTA +1.5% (receives Orphan Drug Designation for necuparanib in pancreatic cancer), ROK +1.3% (Board approved $1 bln common stock repurchase), SPEX +1.1% (has expanded its operations in Texas through the opening of a new office located in Longview, TX.).
Analyst comments: CLVS +3.2% (upgraded to Buy at Stifel), HCLP +2.5% (initiated with a Buy at Jefferies), RATE +1.9% (upgraded to Outperform at RBC Capital Mkts), VGR +1.7% (initiated with a Outperform at Oppenheimer), CATM +1.4% (initiated with a Outperform at Wells Fargo), NBG +1.1% (upgraded to Buy from Hold at Deutsche Bank), ALLT +1% (poistive commentary at OPCO ),MSFT +0.8% (upgraded to Outperform at FBR Capital)
In reaction to strong earnings/guidance: CIEN +12.7%, AXAS +10.1%, VRNT +8.9%, VRA +6.5%, XNY +4.2%, MIXT +4.1%, JOY +3.7%, FIVE +2.9%, BV +2.9%, ( to divest PowerReviews for $30 mln , RLD +2.6%, NAV +1.2%, .
M&A news: S +3.2% (Bloomberg story that Sprint (S) and T-Mobile (TMUS) are near an agreement on price at $40/share, capital structure, and termination fee in potential deal), TMUS +0.9%.
Select Biotechrelated names showing strength: PRAN +9.4%, CPRX +6.9%, ISIS +4.4%, CYTR +1.6%.
Select CIEN peers trading higher: INFN +4.5%, JDSU +2.4%, JNPR +1.3%.
Other news: NEWL +43.5% (announces granting of temporary restraining order against Ironridge Global IV), HALO +15.6% (Halozyme Therapeutics to resume PEGPH20 clinical program in pancreatic cancer; FDA removes clinical hold on Phase 2 trial (study 202), GBLX +14.2% (provides shareholder update; 'will not be selling our GrowBLOX cultivation chambers to the retail consumer'),AXAS +10.1% (raised FY14 production guidance to 5500-5700 Boepd from 5200-5300 Boepd), SSLT +6.3% (still checking), NQ +3.9% (cont strength), TWTR +2.4% (previously considered buying music related companies such as Pandora (P)/Spotify/Soundcloud, according to FT story out yesterday afternoon; also initiated with Outperform at PacCrest), MDCO +2.4% (ORBACTIVTM Phase 3 trial results published in New England Journal of Medicine), SPR +2.2% (announced public secondary offering of ~8.17 mln shares of Class A common stock by selling stockholder; co to repurchase 4 mln shares), CETV +2.2% (announces the appointment of David Sturgeon as CFO), STO +2% (still checking), ORAN +2% (won a global wide area network and embedded security services contract with Oetiker Group), OLED +1.8% (Board of directors approved $50 mln common stock repurchase program), MNTA +1.5% (receives Orphan Drug Designation for necuparanib in pancreatic cancer), ROK +1.3% (Board approved $1 bln common stock repurchase), SPEX +1.1% (has expanded its operations in Texas through the opening of a new office located in Longview, TX.).
Analyst comments: CLVS +3.2% (upgraded to Buy at Stifel), HCLP +2.5% (initiated with a Buy at Jefferies), RATE +1.9% (upgraded to Outperform at RBC Capital Mkts), VGR +1.7% (initiated with a Outperform at Oppenheimer), CATM +1.4% (initiated with a Outperform at Wells Fargo), NBG +1.1% (upgraded to Buy from Hold at Deutsche Bank), ALLT +1% (poistive commentary at OPCO ),MSFT +0.8% (upgraded to Outperform at FBR Capital)